Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
06:34am, Thursday, 07'th Nov 2024
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial vi
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
06:30am, Thursday, 07'th Nov 2024
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
01:37am, Thursday, 07'th Nov 2024
Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
04:00pm, Wednesday, 06'th Nov 2024
Perhaps this list is a good place to start bargain-hunting.
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
04:11am, Wednesday, 06'th Nov 2024
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
04:00pm, Tuesday, 05'th Nov 2024
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
Moderna CEO Bancel steps down as sales chief, Bloomberg Law reports
12:26pm, Tuesday, 05'th Nov 2024
Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar with the ma
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
09:31am, Tuesday, 05'th Nov 2024
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
09:05am, Tuesday, 05'th Nov 2024
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
11:05am, Thursday, 31'st Oct 2024
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
06:56pm, Tuesday, 29'th Oct 2024
In the most recent trading session, Moderna (MRNA) closed at $55.22, indicating a +0.77% shift from the previous trading day.
mRNA Synthesis & Manufacturing Market to Hit USD 2958.3 million by 2029 with 5.8% CAGR | MarketsandMarkets™
08:30am, Tuesday, 29'th Oct 2024
Delray Beach, FL, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The global mRNA synthesis and manufacturing market is projected to grow from USD 2,231.4 million in 2024 to USD 2,958.3 million by 2029, at a CAGR o
Moderna Stock Price Target Slashed. It's About Vaccines.
07:53am, Monday, 28'th Oct 2024
The drug maker's shares have dropped 46% so far this year and 56% in the past three months.
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiatio
Moderna Named a Top Employer by Science for Tenth Consecutive Year
02:25pm, Thursday, 24'th Oct 2024
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 202
